Navigation Links
Boehringer Ingelheim and Xencor Enter a Collaboration Agreement for the Development, Manufacture, and Supply of Biosuperior Monoclonal Antibodies
Date:2/21/2012

MONROVIA, Calif. and INGELHEIM, Germany, Feb. 21, 2012 /PRNewswire/ -- Xencor, Inc., a company using its proprietary Protein Design Automation® (PDA) platform technology to engineer next-generation antibodies, and Boehringer Ingelheim announced today a collaboration agreement for certain Xencor biosuperior monoclonal antibodies. Under the terms of the agreement, Boehringer Ingelheim will provide all manufacturing and product supply from preclinical through Phase 1 development.  Xencor is responsible for preclinical and clinical studies and retains all development and commercial rights to products under the agreement. Upon successful advancement of clinical programs beyond Phase 1 development, Boehringer Ingelheim has certain manufacturing rights to supply clinical and commercial material to Xencor.

"Xencor has developed a deep portfolio of biosuperior antibodies with the potential for superior clinical and commercial performance, and this collaboration agreement with Boehringer Ingelheim allows us to establish an important relationship with the leading global contract manufacturer of biologics," said Bassil Dahiyat, Ph.D., president and CEO of Xencor.  "Xencor and Boehringer Ingelheim will share the financial risk in early preclinical and clinical development with the incentive of sharing in future success of the programs."

"We are delighted to start this collaboration with Xencor. It reflects one of our new business models in the contract manufacturing in which both parties are enabled to focus on their core competencies," stated Corporate Senior Vice President Simon Sturge at Boehringer Ingelheim Biopharmaceuticals."We are convinced that this creates a win-win situation for both parties."

Xencor's lead biosuperior compound is an anti-TNF antibody engineered using the company's proprietary Xtend™ antibody engineering technology for increasing antibody half-life. Xencor expects to initiate a Phase 1 trial in 20
'/>"/>

SOURCE Xencor, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CompleGen Announces Successful Delivery of Its XenoGene™ Technology to Boehringer Ingelheim for Drug Discovery Under a Non-Exclusive Agreement.
2. AbGenomics International, Inc. Regains Global Rights to AbGn-168H from Boehringer Ingelheim
3. Boehringer Ingelheim Invests More Than $350 Million in 2011 U.S. Expansion Projects
4. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
5. Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
6. Boehringer Ingelheim Broadens Its Breast Cancer Clinical Trial Program for the Investigational Compound Afatinib
7. Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves
8. Boehringer Ingelheim and Ashokas Changemakers Launch "Making More Health" Competition
9. Ashoka and Boehringer Ingelheim Announce a Global Partnership for "Making More Health"
10. Zealand Pharma and Boehringer Ingelheim Enter Into a Licence and Collaboration Agreement to Advance Novel Compounds to Treat Type-2 Diabetes and Obesity
11. Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 CHINA ... Senior Care, Rehabilitation Medicine and Healthcare, second to none ... will be held at Shanghai New International Expo Center ... 2015,  Implementation Suggestions on Encouraging Private Capital to Participate ... was jointly issued by the Ministry of Civil Affairs of ...
(Date:3/27/2015)... 2015  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... previously announced registered offering of common shares in ... to the Offering, the Company issued 7,286,432 common shares ... gross proceeds of approximately $1.45 billion. On March 18, ... Exchange Commission a final prospectus supplement to its effective ...
(Date:3/27/2015)... 2015 As of February, InControl Medical, ... for women. "Shipping thousands of our ... is the hundreds of letters, emails and phone ... been positively impacted by our technology," said ... InControl recently released Apex, an over-the-counter solution for ...
Breaking Medicine Technology:CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 2CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 3CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 4CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 5CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 6Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2
(Date:3/28/2015)... 2015 The "Petrick Sustainable Health ... health. After 18 years of research and experience with ... contenders, Dr. Jon Petrick is excited to be launching ... of the immediate benefits of this radical new system ... of strength of the immune system, faster healing of ...
(Date:3/28/2015)... March 28, 2015 Purity Products®, ... supplements announces the release of their revolutionary new ... in two randomized, double-blind, placebo-controlled clinical studies to ... and hip size. MuffinStop™ is a combination of ... Garcinia mangostana, fused together to create one of ...
(Date:3/27/2015)... The Monogamy Method - a ... and Jason Rogers has just been released to the ... commotion surrounding the course's launch has caught the attention ... in-depth review of the new program. , "Many women ... lives suddenly start pulling away or expressing interest in ...
(Date:3/27/2015)... Florida Hospital is excited to continue its partnership ... care provider for the 2015 and 2016 season. As the ... and an athletic trainer for the team throughout each season. ... against the Cleveland Gladiators at Amalie Arena; the game starts ... to us as it gives us the opportunity, to provide ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Bleeding ... patients undergoing percutaneous coronary intervention (PCI), resulting in ... observed a “risk-treatment paradox,” in which the highest-risk ... treatment are treated less often with bleeding avoidance ... Saint Luke’s Mid America Heart Institute asked the ...
Breaking Medicine News(10 mins):Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 3Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3
... Hall of Fame inductees Jackson Browne and Graham Nash ... biggest problem: the health of our peopleWASHINGTON, Jan. 6 ... The Vineeta Foundation, a health and human rights organization, ... the Health for All Blue Diamond Ball will be ...
... FASgen, Inc. is pleased to announce that it has ... Inc. This agreement will give Centocor, Inc. and ... the opportunity to discover and develop novel small molecule ... selective inhibition of Fatty Acid Synthase (FAS) for ...
... 6 Nanotechnology can be described as,the ... changing the way many,industries think of surface ... boat hull, a self-cleaning aircraft or a ... commercial reality using nanotechnology,materials and concepts. Nanovere ...
... Heine and Riester, giving physicians and researchers a one-stop online shop ... ... (Vocus) January 6, 2009 -- ORSupply.com, the largest online marketplace for ... unveiling a new range of otoscopes from Welch Allyn, Heine, and ...
... of member self-scheduling via the Internet , ... ... the industry leader in online customer self-scheduling software, announced several ... base. Major program providers such as Lifecare, Inc., which ...
... Jan. 6 Dr. Siegal,s Direct Nutritionals, ... ) and,worldwide distributor of the internationally-popular Dr. ... products, today announced,that renowned physician, author, and ... attend a grand opening event at the ...
Cached Medicine News:Health News:Health for All Blue Diamond Ball Scheduled to Celebrate Obama's Inauguration 2Health News:FASgen, Inc. Announces Research and License Agreement With Centocor, Inc. 2Health News:Nanotechnology Causes Disruption - Cross Industry 2Health News:ORSupply.com Unveils Largest Selection of Otoscopes Available Anywhere 2Health News:ORSupply.com Unveils Largest Selection of Otoscopes Available Anywhere 3Health News:Online Scheduling Software Is Revolutionizing the Wellness Industry 2Health News:Dr. Sanford Siegal and Weight Loss Success Story Josie Raper, Who Appears on Current People Magazine Cover, to Attend Grand Opening of Dr. Siegal's COOKIE DIET Store in Beverly Hills 2
... Gemini surgical headlight is perfectly balanced and ... and ultra-low-profile and illuminates brilliantly while allowing ... "rams effect." The fully adjustable headband, made ... sit low on the brow, directing the ...
... The use of some micro vascular ... and thrombosis. With use, Stainless steel changes ... is known that pressures above 30g/mm2 may ... are made from titanium which does not ...
... our family of halogen lightsources , ... ... ... two surgeons to work simultaneously from it, while the third lamp is reserved for backup. Designed ...
... Bring the clarity of daylight into ... Xenon Light Source. Designed for a variety ... endoscopic instruments, and video equipment - this ... at 300 watts (6,000o K) for superb ...
Medicine Products: